drugset / Trial / NCT00849862
Levetiracetam 750 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The objective of this study is to compare the rate and extent of absorption of a test formulation of Levetiracetam and the reference Keppra® administered as a 1 x 750 mg tablet under fasting conditions.
Timeline
- Start
- 2005-10
- Primary completion
- 2005-11
- Completion
- 2005-11
Outcome
Met primary endpoint
registry Geometric Test/Ref Ratio x 100 92.2 (90% CI 85.0 to 100) NCT00849862 ↗
registry Geometric Test/Ref Ratio x 100 100 (90% CI 96.3 to 104) NCT00849862 ↗
registry Geometric Test/Ref Ratio x 100 99.6 (90% CI 96.2 to 103) NCT00849862 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levetiracetam | Other / unclassified | 750 mg | — |
Indications
No indication recorded.